Latest Bayer HealthCare Stories
In Honor of Mother's Day, Campaign Looks to Raise $200,000 for WomenHeart and Awareness Among 42 Million Women With or at Risk of Heart Disease MORRISTOWN, N.J., May 7, 2013 /PRNewswire/ -- Bayer HealthCare, the makers of Bayer® Aspirin, WomenHeart: The National Coalition for Women with Heart Disease, and actress, singer and author Vanessa Williams today announce their partnership to launch Handbags & Hearts, a national campaign that leverages the link between women and their...
Senior Executive at Bayer Healthcare, Mars Global PetCare and Banfield Pet Hospitals brings decades of experience to nation's leading charity protecting children and animals WASHINGTON, March 22, 2013 /PRNewswire-USNewswire/ -- Global animal healthcare leader John Payne, who has served in top positions at Bayer Healthcare, Mars Global PetCare, and Banfield Pet Hospitals, has been named chairman of the board at American Humane Association, the country's first national humane...
TARRYTOWN, N.Y. and BERLIN, Feb. 19, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that they have initiated a new Phase 3 trial (named VIVID EAST-DME) to evaluate the efficacy and safety of EYLEA(®) (aflibercept) Injection in the treatment of Diabetic Macular Edema (DME) in Russia, China, and other Asian countries. The companies are extending their global development program for EYLEA in DME after promising results in the...
TARRYTOWN, N.Y. and BERLIN, Dec. 6, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for EYLEA (aflibercept) Injection for the treatment of macular edema following Central Retinal Vein Occlusion (CRVO). "It is our pleasure to announce the filing for EYLEA for the macular edema following CRVO indication with the European Regulatory...
TARRYTOWN, N.Y., Nov. 27, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA(®) (aflibercept) Injection has been approved by the European Commission for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD). According to the European Medicines Agency (EMA) approved Summary of Product Characteristics, EYLEA treatment is initiated with one 2 milligram (mg) injection per month for three consecutive...
HILDEN, Germany, October 25, 2012 /PRNewswire/ -- - QIAGEN and Bayer HealthCare signed collaboration agreement aimed at advancing both companies positions in personalized medicine - The programs pair QIAGEN companion diagnostic solutions with innovative targeted therapies for patients with solid tumors developed by Bayer HealthCare - Agreement provides framework for further collaboration projects QIAGEN (NASDAQ: QGEN;...
TARRYTOWN, N.Y., Sept. 28, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that EYLEA(®) (aflibercept) Injection has received approval for the treatment of patients with neovascular age-related macular degeneration (wet AMD) from the Japanese Ministry of Health, Labour and Welfare (MHLW). In Japan, EYLEA treatment is initiated with one 2 milligram (mg) intravitreal injection per month for three consecutive months (treatment initiation)....
TARRYTOWN, N.Y., Sept. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA(®) (aflibercept) Injection has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD). The decision of the European Commission on approval is expected in the fourth quarter of 2012. "We are pleased with the positive...
MORRISTOWN, N.J., Sept. 4, 2012 /PRNewswire/ -- Bayer HealthCare's Consumer Care Division announced today the introduction of Bayer®( )Migraine Formula, an over-the-counter (OTC) medication designed to relieve migraine pain and accompanying symptoms - nausea, phonophobia (sound sensitivity) and photophobia (light sensitivity). The powerful triple action formula of aspirin, acetaminophen and caffeine aims to target and alleviate tough migraine pain fast and effectively. (Logo:...
MORRISTOWN, N.J., June 26, 2012 /PRNewswire/ -- Today, All-Star Major League Baseball (MLB) pitcher CC Sabathia teamed up with the makers of Bayer® Advanced Aspirin to issue the Fast Relief Challenge to help support the American Red Cross and its efforts to provide fast relief to Americans in need. For every person who visits www.FastReliefChallenge.com and clicks on the Red Cross button, the makers of Bayer Advanced Aspirin will donate $2 to the American Red Cross (up to a total...
